Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials

PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

(2020) Baruch D. Kuppermann et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Drug Delivery to the Posterior Segment of the Eye: Biopharmaceutic and Pharmacokinetic Considerations

(2020) Rubén Varela-Fernández et al.   Pharmaceutics

Topical Brimonidine or Intravitreal BDNF, CNTF, or bFGF Protect Cones Against Phototoxicity

(2019) Francisco J. Valiente-Soriano et al.   Translational Vision Science & Technology

Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial

(2018) Rafael Simó et al.   DIABETES

Pharmacokinetic aspects of retinal drug delivery

(2017) Eva M. del Amo et al.   PROGRESS IN RETINAL AND EYE RESEARCH

The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits

(2016) Keisuke Shinno et al.   CURRENT EYE RESEARCH

Brimonidine Can PreventIn VitroHydroquinone Damage on Retinal Pigment Epithelium Cells and Retinal Müller Cells

(2016) Claudio Ramírez et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

A comprehensive insight on ocular pharmacokinetics

(2016) Vibhuti Agrahari et al.   Drug Delivery and Translational Research

Neuroprotection by α2-Adrenergic Receptor Stimulation after Excitotoxic Retinal Injury: A Study of the Total Population of Retinal Ganglion Cells and Their Distribution in the Chicken Retina

(2016) Caridad Galindo-Romero et al.   PLoS One

Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data

(2015) Eva M. del Amo et al.   EXPERIMENTAL EYE RESEARCH

Comparison of ocular tissue weights (volumes) and tissue collection techniques in commonly used preclinical animal species.

(2014) C STRUBLE et al.   ACTA OPHTHALMOLOGICA

A Novel In Vivo Model of Focal Light Emitting Diode-Induced Cone-Photoreceptor Phototoxicity: Neuroprotection Afforded by Brimonidine, BDNF, PEDF or bFGF

(2014) Arturo Ortín-Martínez et al.   PLoS One

A Randomized Trial of Brimonidine Versus Timolol in Preserving Visual Function: Results From the Low-pressure Glaucoma Treatment Study

(2011) Theodore Krupin et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Experimental and Clinical Evidence for Brimonidine as an Optic Nerve and Retinal Neuroprotective Agent

(2009) Meredith Saylor   ARCHIVES OF OPHTHALMOLOGY

Ophthalmic Drug Delivery: Development and Regulatory Considerations

(2009) GD Novack   CLINICAL PHARMACOLOGY & THERAPEUTICS

Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments

(2008) María Hernández et al.   EXPERIMENTAL EYE RESEARCH

A Pilot Study of Topical Treatment with an alpha2-agonist in Patients with Retinal Dystrophies

(2008) Saul Merin et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations

(2008) Brian G. Short   TOXICOLOGIC PATHOLOGY